Orexigen Therapeutics Inc. reported higher-than-expected second quarter revenues, helped by royalties on U.S. sales of obesity drug Contrave (naltrexone and bupropion). Shares rose (NASDAQ:OREX) 35 cents, to $4.17 by Thursday's close as the company settled a dispute with its North American partner Takeda Pharmaceutical Co Ltd. and signed a new distribution deal for South Korea.